Court Orders Disclosure of Regulatory Documents in Bio-Similar Drug Dispute

Overview of the Case

In a significant ruling, the High Court of Delhi has ordered the disclosure of regulatory documents related to the approval of bio-similar drugs, amidst ongoing litigation between F. Hoffmann-La Roche Ltd. and its affiliates against Hetero Drugs Limited and Cadila Healthcare Limited . The judgment, pronounced by Justice AmitBansal on February 18, 2025, addresses two connected suits: CS(COMM) 540/2016 (Hetero Suit) and CS(COMM) 1119/2016 ( Cadila Suit).

Background

The plaintiffs, a consortium of companies known for developing biological drugs for cancer treatment, have accused the defendants of unlawfully obtaining approvals for their bio-similar versions of the plaintiffs' drugs, bevacizumab and trastuzumab . The plaintiffs seek a permanent injunction against the defendants from marketing these drugs, claiming that the approvals granted by the Drug Controller General of India (DCGI) were based on inadequate clinical trials and misrepresentation of bio-similarity.

Arguments Presented

Plaintiffs' Position

The plaintiffs, represented by senior advocates Sandeep Sethi and Darpan Wadhwa , argued that:

• The defendants' drugs are marketed for serious medical conditions, necessitating full disclosure of trial data to ensure public safety.
• The approvals obtained by the defendants were invalid due to the alleged suppression of material facts and failure to conduct independent tests as required by the Drugs and Cosmetics Act, 1940 and the Bio-similar Guidelines, 2012 .
• The plaintiffs cited previous judgments, including Genentech v. DCGI , to support their claim for document discovery, emphasizing that the documents sought are crucial for adjudicating the case.

Defendants' Counterarguments

The defendants, represented by senior advocates C.M. Lall and J. Sai Deepak , contended that:

• The plaintiffs were attempting a "fishing expedition" to access sensitive proprietary information that had no bearing on the case.
• The approvals for their drugs were granted following due process under the Bio-similar Guidelines, and the plaintiffs could not claim exclusivity over expired patents.
• They argued that the plaintiffs failed to establish a prima facie case, as required under Section 104A of the Patents Act, 1970 , for the discovery of documents.

Court's Reasoning

Justice Bansal emphasized that the discovery of documents is essential for a fair trial, stating:

> "The only issue to be considered by the Court while adjudicating an application for interrogatories or discovery of documents is whether the answer to such an application would have a bearing on the determination of the dispute between the parties."

The court found that the documents requested by the plaintiffs were relevant to the issues at hand, particularly regarding the validity of the clinical trials conducted by the defendants and the legality of the approvals granted by the DCGI.

Final Decision and Implications

The court ruled in favor of the plaintiffs, directing Hetero and Cadila to produce the requested documents within four weeks. The judgment underscores the importance of transparency in the pharmaceutical industry, particularly concerning the approval processes for drugs that impact public health.

The formation of confidentiality clubs was also mandated to ensure that sensitive information is handled appropriately during the discovery process.

This ruling sets a precedent for future cases involving bio-similar drugs and highlights the judiciary's role in ensuring regulatory compliance and protecting public interest in the pharmaceutical sector.

Key Details

• Bench : Justice AmitBansal
• Case Timeline : Ongoing since 2016
• Legal Sections Invoked : Drugs and Cosmetics Act, Bio-similar Guidelines, Patents Act
• Relevant Precedents : Genentech v. DCGI, Roche India Pvt Ltd v. DCGI

The court's decision is a pivotal moment in the ongoing battle over bio-similar drug approvals, reinforcing the need for rigorous scrutiny of regulatory processes in the pharmaceutical industry.